1b9w: Difference between revisions
New page: left|200px<br /><applet load="1b9w" size="450" color="white" frame="true" align="right" spinBox="true" caption="1b9w, resolution 1.800Å" /> '''C-TERMINAL MEROZOIT... |
No edit summary |
||
Line 1: | Line 1: | ||
[[Image:1b9w.jpg|left|200px]]<br /><applet load="1b9w" size=" | [[Image:1b9w.jpg|left|200px]]<br /><applet load="1b9w" size="350" color="white" frame="true" align="right" spinBox="true" | ||
caption="1b9w, resolution 1.800Å" /> | caption="1b9w, resolution 1.800Å" /> | ||
'''C-TERMINAL MEROZOITE SURFACE PROTEIN 1 FROM PLASMODIUM CYNOMOLGI'''<br /> | '''C-TERMINAL MEROZOITE SURFACE PROTEIN 1 FROM PLASMODIUM CYNOMOLGI'''<br /> | ||
==Overview== | ==Overview== | ||
The C-terminal proteolytic processing product of merozoite surface protein | The C-terminal proteolytic processing product of merozoite surface protein 1 (MSP1) appears essential for successful erythrocyte invasion by the malarial parasite, Plasmodium. We have determined the crystal structure at 1.8 A resolution of a soluble baculovirus-recombinant form of the protein from P. cynomolgi, which confers excellent protective efficacy in primate vaccination trials. The structure comprises two EGF-like domains, and sequence comparisons strongly suggest that the same conformation is present in all species of Plasmodium, including P. falciparum and P. vivax, which are pathogenic in man. In particular, conserved interdomain contacts between the two EGF modules should preserve the compact form of the molecule in all species. Implications of the crystal structure for anti-malarial vaccine development are discussed. | ||
==About this Structure== | ==About this Structure== | ||
1B9W is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Plasmodium_cynomolgi Plasmodium cynomolgi]. Full crystallographic information is available from [http:// | 1B9W is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Plasmodium_cynomolgi Plasmodium cynomolgi]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1B9W OCA]. | ||
==Reference== | ==Reference== | ||
Line 13: | Line 13: | ||
[[Category: Plasmodium cynomolgi]] | [[Category: Plasmodium cynomolgi]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
[[Category: Bentley, G | [[Category: Bentley, G A.]] | ||
[[Category: Chitarra, V.]] | [[Category: Chitarra, V.]] | ||
[[Category: Holm, I.]] | [[Category: Holm, I.]] | ||
Line 21: | Line 21: | ||
[[Category: surface antigen]] | [[Category: surface antigen]] | ||
''Page seeded by [http:// | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 11:53:03 2008'' |
Revision as of 12:53, 21 February 2008
|
C-TERMINAL MEROZOITE SURFACE PROTEIN 1 FROM PLASMODIUM CYNOMOLGI
OverviewOverview
The C-terminal proteolytic processing product of merozoite surface protein 1 (MSP1) appears essential for successful erythrocyte invasion by the malarial parasite, Plasmodium. We have determined the crystal structure at 1.8 A resolution of a soluble baculovirus-recombinant form of the protein from P. cynomolgi, which confers excellent protective efficacy in primate vaccination trials. The structure comprises two EGF-like domains, and sequence comparisons strongly suggest that the same conformation is present in all species of Plasmodium, including P. falciparum and P. vivax, which are pathogenic in man. In particular, conserved interdomain contacts between the two EGF modules should preserve the compact form of the molecule in all species. Implications of the crystal structure for anti-malarial vaccine development are discussed.
About this StructureAbout this Structure
1B9W is a Single protein structure of sequence from Plasmodium cynomolgi. Full crystallographic information is available from OCA.
ReferenceReference
The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate., Chitarra V, Holm I, Bentley GA, Petres S, Longacre S, Mol Cell. 1999 Apr;3(4):457-64. PMID:10230398
Page seeded by OCA on Thu Feb 21 11:53:03 2008